Clinical trial
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child…
NCT00270296 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00270296 |
|---|---|
| Title | Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV |
| Official title | Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Harvard School of Public Health (HSPH) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Trizivir, Lamivudine/Zidovudine, Lopinavir/Ritonavir, Nevirapine |
| Enrollment | 730 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 2, 2021 |
| Countries | Botswana |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: